In a patient with a coronary stent on dual antiplatelet therapy who sustains a head injury, how should aspirin and the P2Y12 inhibitor be managed regarding continuation, discontinuation, and timing of resumption?

Management of Dual Antiplatelet Therapy in Head Injury

In a patient with a coronary stent on dual antiplatelet therapy (DAPT) who sustains a head injury, aspirin should be continued if possible while the P2Y12 inhibitor should be discontinued immediately, with both agents restarted as soon as clinically safe based on neurosurgical assessment and imaging findings.

Immediate Management Algorithm

Step 1: Initial Assessment and Discontinuation Decision

When a head injury occurs in a patient on DAPT:

• Discontinue the P2Y12 inhibitor immediately if there is any evidence of intracranial bleeding or significant risk thereof 1, 2
• Continue aspirin if bleeding risk permits, as aspirin provides critical protection against stent thrombosis with lower bleeding risk than dual therapy 1, 2
• Obtain urgent neuroimaging (CT head) to assess for intracranial hemorrhage
• Determine time since stent placement and stent type (critical for risk stratification)

Step 2: Risk Stratification Based on Stent Timing

The decision heavily depends on when the stent was placed:

Within 4-6 weeks of stent placement (highest risk period):

• This is the most dangerous scenario - stent thrombosis risk is extremely high 2, 3
• If no intracranial bleeding is present, strongly consider continuing DAPT unless bleeding risk is catastrophic
• Requires consensus discussion between neurosurgery, cardiology, and the patient/family 1, 2
• The consequences of stent thrombosis (death, massive MI) often outweigh bleeding risks except in severe intracranial hemorrhage 4

6 weeks to 6 months post-stent:

• Stent thrombosis risk remains elevated but decreasing 2
• Stop P2Y12 inhibitor, continue aspirin is the preferred approach 1, 2
• Monitor closely for both bleeding progression and cardiac ischemia

Beyond 6 months post-stent:

• Stent thrombosis risk is substantially lower 2
• Stop P2Y12 inhibitor, continue aspirin unless severe intracranial bleeding mandates stopping both 1

Step 3: Management Based on Bleeding Severity

No intracranial bleeding on imaging:

• Continue aspirin indefinitely 5
• Hold P2Y12 inhibitor temporarily
• Resume P2Y12 inhibitor within 24-48 hours if neurologically stable and no delayed bleeding

Intracranial bleeding present:

• Stop both agents immediately - this is the one scenario where stent thrombosis risk must be accepted 1
• Consider platelet transfusion if neurosurgical intervention needed
• Neurosurgical consultation for operative vs. conservative management

Subdural hematoma or other contained bleeding:

• Stop P2Y12 inhibitor completely 1
• Consider stopping aspirin temporarily (3-4 days) then resuming 4
• Serial imaging to ensure stability before restarting antiplatelet therapy

Timing of Resumption

P2Y12 Inhibitor:

• Resume as soon as possible after neurosurgical clearance 1, 2, 3
• Ideally within 24-48 hours if no active bleeding and stable imaging 6
• For clopidogrel: can resume at 75mg daily (no reloading needed in stable patients)
• For prasugrel/ticagrelor: resume at maintenance dose

Aspirin:

• Should be continued throughout if at all possible 1, 7, 2
• If stopped, resume within 24 hours of hemostasis 6
• Use 81mg daily dose (lower bleeding risk than higher doses) 5, 3

Critical Pitfalls to Avoid

1. Never delay resumption unnecessarily - each day off DAPT in the early post-stent period exponentially increases thrombosis risk 8, 3

2. Do not use "bridging" with GP IIb/IIIa inhibitors or cangrelor routinely - no proven benefit and increases bleeding 6, 9. Consider only in very high-risk scenarios (recent stent in critical location) 6

3. Do not stop both agents reflexively - aspirin alone provides substantial protection and has acceptable bleeding risk in most head injuries without intracranial hemorrhage 1, 2

4. Avoid the temptation to keep patients off antiplatelet therapy "to be safe" - stent thrombosis mortality approaches 45% and often occurs suddenly 8

Special Considerations

For intracranial surgery specifically:

• This represents the highest bleeding risk scenario 4
• Stop both agents if surgery required 4
• Consider very brief interruption (3-4 days for aspirin) with resumption immediately post-op if hemostasis achieved 4
• May consider bridging with short-acting IV agents (cangrelor) in extremely high-risk stent situations, though evidence is limited 6, 9, 4

ACS vs. stable CAD context:

• Patients who had ACS at time of stenting are at higher thrombotic risk 3
• Even more critical to resume therapy quickly in ACS patients 3

Drug-eluting vs. bare-metal stents:

• Drug-eluting stents have higher thrombosis risk, especially in first 6 months 8, 3
• Bare-metal stents: highest risk is first 30 days, then substantially lower 5, 8

The fundamental principle is that stent thrombosis is often fatal, while most bleeding complications are manageable - this should guide decision-making except in cases of severe intracranial hemorrhage requiring surgical intervention 4, 10.